ENBREL Safety Profile

10+ years of continuous safety data in RA¹

In moderate to severe rheumatoid arthritis patients and psoriatic arthritis patients taking ENBREL, malignancy, serious infection, and opportunistic infection rates were similar to rates of the control in the pivotal clinical trials.¹

Important Safety Considerations

ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis.

See Important Safety Information for additional information.

Learn more about:

Malignancies
Serious and Opportunistic Infections
Tuberculosis

Important Safety Information Psoriatic Arthritis Safety Profile

Important Safety Information Prescribing Information Medication Guide

Indications

Moderate to Severe Rheumatoid Arthritis Supportive Data

ENBREL offers the convenience and flexibility of 4 injection options

Show your patients video demonstrations of each self-administration method.

View ENBREL dosing and administration

ENBREL for moderate to severe rheumatoid arthritis: Safety profile

Serious adverse events and serious infection rates were similar to control and consistent over time.

View rheumatoid arthritis safety profile

Finding a treatment that has worked for me has motivated me to share my story. Results may vary.

Phil Mickelson, Champion golfer and ENBREL PsA patient since 2010

Prescribing Information Medication Guide

You are leaving Enbrel.com/RheumPro

Please know that Amgen and Pfizer do not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

Continue Cancel

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy Terms of Use
This site is intended for US Audiences only.
©2011 Amgen, Inc., Thousand Oaks, CA 91320 and Pfizer Inc

Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

Continue

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.